Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 03 / 17
Fangda Assists GHT (300711.SZ) in Private Placement of A Shares
2026 / 03 / 12
Fangda Represents Major Creditors in a Real Estate Bankruptcy Liquidation Included in the Supreme People’s Court Work Report, Helping Revitalize Tianjin’s Tallest Skyscraper
2026 / 03 / 09
Fangda Assists Zhaowei Machinery & Electronics in Listing on the Main Board of The Stock Exchange of Hong Kong
2026 / 03 / 06
Fangda Acts as Administrator in Red Star Holdings’ Successful Restructuring — Selected as a 2025 Typical Bankruptcy Adjudication Case in Pudong
2026 / 02 / 26
Fangda Advises CVC on EUR 2.2 Billion Carve-Out Acquisition of dsm-firmenich’s Animal Nutrition & Health Business
